Abstract Library

#4234 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occurs sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Haider M, Strosberg J,

Keywords: gastric, ppi, neuroendocrine, type 3 gastric net,

#4104 Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

Introduction: Lung cancer (LC) remains one of the most prevalent and deadly cancers worldwide. Neuroendocrine differentiation (NED) is observed in 25-33% of LC cases. NSCLC patients with NED (NSCLC-NED) often have worse outcomes, resembling SCLC behaviour.

Conference:

Presenting Author:

Authors: Chai M, Zhang Y, Wang Y, Lu Z, Xie J,

Keywords: NSCLC-NED, treatment, surufatinib, vinorelbine,

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,

#3558 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occure sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated tumors.

Conference:

Presenting Author:

Authors: Al-Toubah T, Pelle E, Strosberg J,

Keywords: gastric carcinoid, ppi, gastric, NET, type 2, type 3, type 1,

#3458 Post-PRRT imaging: Which scans to make and what to look for

Introduction: Post-PRRT imaging often focuses on dosimetry but seldom on its clinical utility.

Conference:

Presenting Author: Aalbersberg E

Authors: Aalbersberg E, Huizing D, Tesselaar M, Stokkel M, Versleijen M,

Keywords: PRRT,